A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)"
2014
Circulation
Preserved Fulltext
postulate that the 21% reduction in mortality observed in patients with idiopathic (IPAH) pulmonary arterial hypertension (PAH) who received anticoagulants was mainly the result of immortal time bias rather than a true drug effect. We can assure them that this was not the case. Anticoagulation was started within 3 months after diagnosis in 92.4% of all patients (94.8% after 6 months and 97.4% after 12 months).
doi:10.1161/circulationaha.114.010921
pmid:25223780
fatcat:rkasapnpznbvhbiicddl36njze